Published Articles & Presentations
Published Articles & Presentations
The information in our publications and presentations should be considered accurate only as of the date of the publications or presentations. We disclaim any obligation to supplement or update the information in these publications and presentations.
To learn more about our innovative technology:
The objective of this study is to compare plasma exposure in the first two hours following administration of dihydroergotamine mesylate (DHE) by INP104 (POD® nasal), Migranal® Nasal Spray, D.H.E. 45® (IV) or MAP0004 (oral inhalation) using data obtained from the…
READ MORE
DHE is effective for acute migraine. The approved label warns of potential cardiovascular effects although the clinical experience of DHE over 70 years of use has been good. Work has shown the high Cmax of IV DHE may account for…
READ MORE
Dihydroergotamine mesylate was approved in 1946 for the treatment of migraine and for the next 40 years was available as the most specific, acute anti-migraine therapy until the advent of the Triptans. DHE is still used today, available in multiple…
READ MORE
